THRASOS LIMITED is a bio-therapeutics company focused on pioneering targeted therapies to prevent and treat severe organ failure, with a specific emphasis on kidney disease. Founded in 2002, the company's primary therapeutic program, THR-184, is designed to prevent and treat acute kidney injury (AKI). Thrasos is also actively developing a preclinical program to address chronic kidney disease (CKD).
The company's dedication to discovering and developing targeted therapies in the Biotechnology, Health Care, Health and Wellness, and Medical Devices industries has attracted significant investment. Thrasos secured a substantial $21.00M Series D investment on 31 March 2015, with funding from notable investors including Advanced Technology Ventures, Lumira Ventures, MP Healthcare Venture Management, SR One, Pappas Ventures, Fonds de solidarité FTQ, and BDC Healthcare Venture.
Overall, Thrasos Limited's focus on targeted therapies for kidney disease and its impressive investor backing make it a company to watch in the biopharmaceutical space.
